Calquence recommended for approval in the EU by CHMP for chronic lymphocytic leukaemia
Recommendation based on two Phase III trials demonstrating superior progression-free survival across multiple settings while maintaining favourable tolerabilityAstraZeneca’s Calquence (acalabrutinib) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.[1] The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from two Phase III clinical trials, ELEVATE TN in